A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Suvodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man
- Sponsors WaVe life Sciences
- 18 Apr 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 18 Apr 2019 According to a WaVe life Sciences media release, the company will host a conference call today to discuss the results of this trial.
- 16 Apr 2019 Results presented in the WaVe life Sciences media release.